- Stocks
- Healthcare
- NASDAQ: VRTX

Price (delayed)

$267.15

Market cap

$69.27B

P/E Ratio

45.74

Dividend/share

N/A

EPS

$5.84

Enterprise value

$66.21B

The gross profit has grown by 48% YoY and by 16% from the previous quarter

VRTX's revenue is up by 48% YoY and by 16% QoQ

The EPS has declined by 31% year-on-year but it has increased by 28% since the previous quarter

Vertex Pharmaceuticals's net income has decreased by 30% YoY but it has increased by 28% QoQ

The price to earnings (P/E) is 41% more than the last 4 quarters average of 32.5

Vertex Pharmaceuticals's quick ratio has decreased by 8% YoY

What are the main financial stats of VRTX

Market
Valuations
Earnings

Shares outstanding

259.28M

Market cap

$69.27B

Enterprise value

$66.21B

Price to earnings (P/E)

45.74

Price to book (P/B)

10.72

Price to sales (P/S)

14.4

EV/EBIT

36.99

EV/EBITDA

34.91

EV/Sales

13.74

Revenue

$4.82B

EBIT

$1.79B

EBITDA

$1.9B

Free cash flow

$1.98B

Per share
Balance sheet
Liquidity

EPS

$5.84

Free cash flow per share

$7.63

Book value per share

$24.92

Revenue per share

$18.55

TBVPS

$28.83

Total assets

$8.89B

Total liabilities

$2.43B

Debt

$532.95M

Equity

$6.46B

Working capital

$3.91B

Debt to equity

0.08

Current ratio

3.54

Quick ratio

3.27

Net debt/EBITDA

-1.61

Margins
Efficiency
Dividend

EBITDA margin

39.4%

Gross margin

87.2%

Net margin

31.4%

Operating margin

34.2%

Return on assets

19%

Return on equity

26.4%

Return on invested capital

60.5%

Return on capital employed

24.3%

Return on sales

37.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Vertex Pharmaceuticals stock price performed over time

How have Vertex Pharmaceuticals's revenue and profit performed over time

Revenue

$4.82B

Gross profit

$4.2B

Operating income

$1.65B

Net income

$1.51B

Gross margin

87.2%

Net margin

31.4%

The operating income has surged by 110% year-on-year and by 37% since the previous quarter

VRTX's net margin has shrunk by 52% YoY but it is up by 11% QoQ

The gross profit has grown by 48% YoY and by 16% from the previous quarter

VRTX's revenue is up by 48% YoY and by 16% QoQ

What is Vertex Pharmaceuticals stock price valuation

P/E

45.74

P/B

10.72

P/S

14.4

EV/EBIT

36.99

EV/EBITDA

34.91

EV/Sales

13.74

The price to earnings (P/E) is 41% more than the last 4 quarters average of 32.5

The EPS has declined by 31% year-on-year but it has increased by 28% since the previous quarter

The stock's price to book (P/B) is 37% less than its 5-year quarterly average of 17.0 but 18% more than its last 4 quarters average of 9.1

The equity has grown by 37% YoY and by 6% from the previous quarter

VRTX's revenue is up by 48% YoY and by 16% QoQ

The price to sales (P/S) is 11% more than the last 4 quarters average of 13.0 but 11% less than the 5-year quarterly average of 16.1

How efficient is Vertex Pharmaceuticals business performance

The return on invested capital has surged by 80% year-on-year and by 26% since the previous quarter

The return on equity has dropped by 55% year-on-year but it has grown by 18% since the previous quarter

VRTX's return on assets has dropped by 52% year-on-year but it is up by 19% since the previous quarter

The return on sales has surged by 51% year-on-year and by 6% since the previous quarter

What is VRTX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for VRTX.

How did Vertex Pharmaceuticals financials performed over time

Vertex Pharmaceuticals's total assets has increased by 36% YoY and by 7% QoQ

The total liabilities has increased by 34% YoY and by 9% QoQ

VRTX's debt is 92% lower than its equity

The debt to equity fell by 39% YoY and by 11% QoQ

The equity has grown by 37% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.